You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH)一字漲停 研製的法維拉韋獲批上市
格隆匯 02-17 09:27
格隆匯2月17日丨海正藥業(600267.SH)一字漲停報17.17元,盤前成交3374萬元,最新總市值166億元。

海正藥業研製的“法維拉韋”(原名“法匹拉韋”)2月15日正式獲得國家藥監局批准上市。這是疫情期間全國第一個獲批上市的治療新冠肺炎的藥物,預計將對疫情防治發揮重要作用。科技部生物中心主任張新民15日在國務院聯防聯控機制新聞發佈會上介紹,法匹拉韋的臨牀試驗初步顯示了較明顯的療效和較低的不良反應。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account